Maharashtra FDA cancelled the drug sale licence of Cipla’s Pune Carrying and Forwarding unit.
The regulator cited documentation, storage and recall issues at the Pune facility.
One report says the action followed inspection of the Wadki warehouse over Reactin Plus tablets.
Cipla said it has challenged the order and that the matter is sub judice.
Cipla also said the order does not raise concerns about product safety, quality or efficacy.
FDA officials said the department will maintain zero leniency on drug safety and prescription drug distribution.
A quick read on shared facts, changing details, and different emphasis.
All reports agree that Maharashtra FDA cancelled the licence of Cipla’s Pune unit after finding regulatory problems linked to storage, records or recall handling. They also agree that Cipla is contesting the order and denying any product quality or safety concern.
Cipla’s legal challenge means the matter could change if the order is reviewed or stayed. The reports do not settle the underlying dispute over the cited lapses and the company’s response.
Swipe through the perspectives. Labels describe coverage framing, not truth or quality.
The regulator is said to have cancelled Cipla’s Pune licence after finding regulatory lapses involving storage, records and recall procedures. The reports describe the action as linked to inspections of the Wadki warehouse and to concerns over Reactin Plus tablets. Cipla’s position is that it has challenged the order and that no safety, quality or efficacy concern was raised. The coverage presents the dispute as both a regulatory enforcement step and an active legal challenge.
The latest eight dated reports, from earliest to newest.
Business Standard
outlookbusiness.com
The New Indian Express
The Times of India
Attributed summaries from official party channels. These are claims, not independent reporting or fact checks.
Scan each source take, then open the original article.
The Maharashtra Food and Drug Administration reports it has cancelled the drug sale licences for Cipla Pharma and Life Sciences' Pune warehouse due to serious regulatory irregularities. The regulator states the facility failed to comply with recall orders for misbranded Reactin Plus tablets and exhibited poor storage practices, including keeping medicines directly on the floor. FDA Commissioner Tukaram Mundhe emphasized that the department will maintain a policy of zero leniency regarding drug safety and the distribution of prescription medications.
The Maharashtra FDA has revoked the drug sale licence of Cipla's Pune-based Carrying and Forwarding unit citing issues with documentation, storage, and recall procedures. The report notes that the action followed an inspection at the Wadki warehouse regarding Reactin Plus tablets. In response, Cipla stated it has challenged the order and that the matter is currently sub judice. The company also clarified that the regulator's order does not raise concerns regarding the safety, quality, or efficacy of its products.
State authorities have cancelled the drug sale licences of Cipla's facility in Pune after finding violations related to the labelling and recall of the prescription drug Reactin Plus. FDA joint commissioner Ganesh Rokade explained that prohibited labelling could encourage risky self-medication among the public. The regulator also identified operational lapses including inadequate pallet arrangements and discrepancies in purchase-sale records. A Cipla spokesperson confirmed the company is contesting the order while asserting that no product quality or safety issues were alleged.